• Proven results: A patient diagnosed with low-risk multiple myeloma who is treated at the Myeloma Institute can expect to survive more than 10 years.
• Thirty-year history of clinical and research knowledge and experience focused on a single disease—multiple myeloma—and related conditions.
• Routine use of state-of-the-art genetic profiling to molecularly characterize a patient’s disease and then develop a targeted, individualized treatment plan.
• Wealth of robust clinical trials that incorporate novel treatment approaches to push beyond past successes and further improve patient outcomes.
• Dedicated supportive care team for management of disease and treatment complexities.
• Extensive network of support services to facilitate visits for patients traveling to Little Rock.

Curing Multiple Myeloma - The Arkansas Perspective
The issue of curability for multiple myeloma, debated with enthusiasm by some, has been challenged by others preferring to pursue the objective of chronic disease control over disease eradication. Read more